neuro-hormonal interactions in the pancreas have recently been reviewed by Brooks2 and Dupr63.
Three questions about the hormonal control of pancreatic secretion need to be asked: How do pancreatic hormones (insulin and glucagon) affect exocrine pancreatic function (endocrine-exocrine interactions); how do hormones from the gastrointestinal mucosa affect endocrine function of the pancreas (entero-endocrine reactions); how do gastrointestinal hormones affect exocrine pancreatic function (entero-exocrine interactions)?
Endocrine-exocrine Interactions
There is evidence that the pancreatic hormones, insulin and glucagon, influence enzyme synthesis and release in the exocrine pancreas. Acinar cells in the rat pancreas show progressive degranulation and atrophy after repeated injections of glucagon4,5 6. The inhibitory effect of glucagon on pancreatic exocrine secretion was first demonstrated by Zajtchuck and colleagues7. Intravenous glucagon given to two subjects with pancreatic fistulae caused a 90% reduction in pancreatic juice volume and amylase. Dyck and his associates gave physiological doses of glucagon intravenously to the dog8 and mang while stimulating pancreatic secietion with secretin and pancreozymin. Marked inhibition of enzyme output was noted and there was some reduction in volume flow while electrolyte concentrations were unchanged. The effect occurred within a few minutes, indicating inhibition of enzyme release rather than of synthesis. Knight and his coworkers' treated three attacks of acute pancreatitis occurring in two patients with intravenous glucagon and the clinical condition of the patients improved rapidly. One patient received two intravenous injections of glucagon and the abdominal pain disappeared after four hours and the plasma amylase fell after seven hours. The second patient received a loading dose of glucagon followed by a glucagon infusion on two separate occasions. The pain was relieved and the plasma amylases fell after one hour. Although the trial was not controlled and the number of subjects small the results are promising and suggest that further use of the drug in the treatment of acute pancreatitis is indicated.
Progressive damage to pancreatic acinar cells is caused by insulin deficiency. The pancreatic exocrine tissue in diabetic man becomes fibrosed and shows reduced response to hormonal stimulation10""1 and reduced pancreatic Hormonal control ofpancreatic endocrine and exocrine secretion uptake of selenomethionine12"13 the changes being partictlarly marked in insulin-dependent diabetics. Dogs rendered diabetic with anterior pituitary extract14 or alloxanl5 show damage to exocrine tissue, and alloxan given to rats results in a twenty-fold reduction in pancreatic amylase which returns to normal with insulin treatment'6. Insulin also increases synthesis of chymotrypsinogen in the pancreas of normal rats on an exclusively protein diet'6, and it was suggested that insulin controls the synthesis of chymotrypsinogen by favouring the entry of amino acids into the acinar cells and the synthesis of amylase by favouring the entry of glucose. Certainly insulin has been shown to promote amino acid incorporation and protein synthesis in isolated muscle'7 and secreting mammary gland'8. The role of insulin in protein synthesis has recently been reviewed by Wool'9 and Manchester20. There is some morphological evidence to indicate that pancreatic exocrine function may be influenced by pancreatic endocrine hormones. Henderson2' has Several of the hormones released from the intestinal mucosa are capable of stimulating insulin release but it is not yet known which hormone is the main stimulus to insulin secretion after glucose ingestion. The main candidates are secretin, pancreozymin-cholecystokinin, and enteroglucagon, a glucagon-like hormone found in the gastrointestinal mucosa. Blood concentration of a substance with glucagon-like immunoreactivity increases after absorption of glucose from the gut of man'50'5 and dog52 but after intravenous glucose infusion immunoreactive glucagon levels fall51. This suggests that oral glucose stimulates release of immunoreactive glucagon from the gut but that intravenous glucose inhibits release of pancreatic glucagon by a direct effect on the pancreas. A substance with glucagon-like immunoreactivity has been found in the gastrointestinal mucosa53 and has been called 'gut glucagon' or 'enteroglucagon'. This substance has been shown to stimulate insulin release52 and could therefore be the intestinal factor which promotes glucose disposal during absorption from the gut. Cells containing a substance with glucagon-like immunoreactivity have been localized in the gastric fundus and jejunum of the dog using an immunofluorescent technique54. Enteroglucagon can be distinguished from pancreatic glucagon by immunoassay"3'5 and has twice the molecular weight and lacks the effects of pancreatic glucagon on liver glycogenolysis.
Other gastrointestinal hormones may also enhance glucose disposal in response to food in the gut lumen. Ingestion of glucose causes a rapid and large increase in circulating secretin-like activity56 and purified secretin given into the portal vein of the dog57 and man58 or into a peripheral vein59,60 causes a significant rise in insulin release from the pancreas. The role of secretin in the normal physiological response to oral glucose has been cast in doubt by studies which fail to show a rise in plasma insulin after duodenal infusion of acid6'62 and no evidence of exocrine pancreatic stimulation (secretin effect) after intraduodenal glucose in man63. More recently Chisholm and his associates64 have shown that an infusion of hydrochloric acid into the duodenum of man causes elevation of serum secretin and insulin levels. Further studies65 showed that the peak insulin response occurs 30 minutes after the peak secretin level and that the rise in blood insulin is greater and more prolonged than would be expected from the glycaemic stimulus alone or from the short-lived rise in blood secretin level. A continuous secretin infusion before the glucose ingestion was found greatly to potentiate the insulin response. This suggests that secretin has a dual role in insulin release, an early direct stimulation associated with raised secretin levels in the blood, followed by a prolonged potentiation of the glycaemic stimulus to insulin release which continues well after peripheral secretin levels have declined. It has also been shown by studies in vitro66'67 that secretin does not release insulin unless the exocrine pancreas is intact and this could be a further example of the mutual relationship mentioned earlier between the endocrine and exocrine pancreas.
Pancreozymin-cholecystokinin is the third intestinal hormone which may be responsible for the release of insulin after oral glucose68, the stimulus to insulin release in this case being independent of the integrity of the exocrine pancreas67. In addition, pancreozymin-cholecystokinin is the only gastrointestinal hormone that has been shown to stimulate glucagon release from the pancreas57'69. As pancreatic glucagon is a potent stimulus to insulin release"3'34'35, pancreozymin-cholecystokinin could act as the stimulus for insulin secretion by a dual mechanism. It is possible that pancreatic glucagon released by pancreozymin-cholecystokinin partly counteracts insulin promotion of hepatic glycogen synthesis, allowing glucose to be acted on by insulin at peripheral sites.
Thus enteroglucagon, secretin, pancreozymin-cholecystokinin (and probably the chemically similar gastrin) may all fulfil the role of the hypothetical hormone, 'incretin', and act as signals for the release of insulin on the arrival of food in the gastrointestinal tract. Such an action would fill aphysiological need.
Entero-exocrine Interactions
The actions of gastrin, secretin, and pancreozymin-cholecystokinin on the pancreas are well documented but incompletely understood. The mechanisms of release of these hormones have been reviewed recently by Wormsley70. It is known that these hormones have multiple and overlapping effects and the probability that gastrin serves as a direct stimulus to the release of secretin"4 and secretin appears to inhibit gastrin release7' directly makes it likely that pancreatic exocrine secretion is serially controlled by more than one hormone. The synergistic actions between hormones72 73,74 and the difficulty of choosing physiological doses and administering them by way of the physiological portal venous route further complicates investigation. Chemical identification of the major gastrointestinal hormones has led to the development of radioimmunoassay of gastrin75, secretin58, and pancreozymincholecystokinin76, and this technique will be of undoubted value in our further understanding of the physiological roles of these hormones.
The possible role of enteroglucagon in stimulating insulin release has already been mentioned and it seems possible that enteroglucagon, like pancreatic glucagon, inhibits pancreatic exocrine secretion.
Dyck and his associates77 gave intrajejunal glucose to man while stimulating pancreatic secretion with secretin and pancreozymin. Bicarbonate concentration fell by 25% and volume by 50% and the fall was paralleled by a rise in blood levels of immunoreactive glucagon, presumed to be enteroglucagon. There was no change in enzyme concentration, contrasting with the marked fall in enzyme concentration after the intravenous infusion of pancreatic glucagon mentioned earlier8. It was postulated that pancreatic glucagon inhibits enzyme release while enteroglucagon inhibits volume flow and electrolyte secretion by the pancreas. The stimulus for this possible feedback mechanism would be the arrival of food in the intestine. The enteroglucagon released would regulate volume and electrolyte secretion while pancreozymin-cholecystokinin would, as mentioned earlier, stimulate release of pancreatic glucagon which in turn would regulate secretion of enzymes. However, the intrajejunal glucose used in this experiment was in 50% solution and the physiological relevance of the findings remains to be substantiated.
Grossman78 has postulated that gastrin, pancreozymin-cholecystokinin, secretin, and probably glucagon act on one receptor. The receptor has two interacting sites-one with affinity for the chemically similar gastrin and pancreozymin-cholecystokinin and one for secretin and probably the chemically similar glucagon. The hypothesis predicts that all targets that react to one of these hormones will react to the other two and probably glucagon as well. Examples of all these forms of interaction have been found in the study of several of the target sites in the gastrointestinal tract. With the information provided by radioimmunoassay of levels of individual hormones, Grossman's hypothesis should enable a more detailed analysis ofgastrointestinal hormonal action to be made.
Conclusion
The evidence reviewed demonstrates the complexity of the regulation of pancreatic exocrine and endocrine secretions and the difficulty of deciding which of the observed effects are of physiological importance. The hormones stimulating pancreatic exocrine and endocrine secretions interact by competing at the receptor site, by directly stimulating or inhibiting the release of other hormones, and, in the case of insulin, by controlling a-cell responsiveness to hyperglycaemia. It is suggested that hormonal control of insulin release is more important than the direct effect of blood glucose level and that the close anatomical relationship between the pancreatic islets and acinar cells enables locally high concentrations of insulin to promote uptake of amino acids by the acinar cells. The exocrine deficiency in diabetes mellitus may be due in part to lack of the trophic effect of insulin and in part to the raised blood glucagon levels found in this disease. 
